Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 13/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 12/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21688373 | 0.85 | CDK9 (0.56) | CDK9CCNT1FFAR4FFAR1 | |
| SCHEMBL20103466 | 0.81 | CDK9 (0.46) | CDK9CCNT1TSHRMAPK1ALDH1A1 | |
| SCHEMBL20103301 | 0.80 | FFAR4 (0.37) | CDK9CCNT1ALDH1A1FFAR4KDM4E | |
| SCHEMBL2542972 | 0.78 | CDK9 (0.49) | CDK9CCNT1ALOX15TSHRMAPK1 | |
| SCHEMBL20103345 | 0.78 | CDK9 (0.49) | CDK9CCNT1ALOX15TSHRMAPK1 | |
| SCHEMBL2542976 | 0.78 | CDK9 (0.49) | CDK9CCNT1ALOX15TSHRMAPK1 | |
| SCHEMBL20103308 | 0.78 | CCNT1 (0.42) | CDK9CCNT1FFAR4FFAR1 | |
| SCHEMBL18180249 | 0.77 | CDK9 (0.54) | CDK9CCNT1 | |
| SCHEMBL20103395 | 0.77 | ALDH1A1 (0.47) | CDK9CCNT1ALOX15TSHRMAPK1 | |
| SCHEMBL2510859 | 0.76 | CDK9 (0.54) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2018081047-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | CDK9 3507/4885CCNT1 1748/4885ALOX15 1606/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | CDK9 3507/4885CCNT1 1748/4885ALOX15 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.